Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896905 | 1.00 | CYP2D6 (0.32) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL3049591 | 0.84 | PTPRC (0.34) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL1580190 | 0.77 | NOS1 (0.33) | CYP2D6CA2CA1CA7 | |
| SCHEMBL5676122 | 0.74 | — | — | |
| SCHEMBL3283444 | 0.74 | CYP2D6 (0.33) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL2151811 | 0.71 | CYP2D6 (0.31) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL10512876 | 0.71 | DGAT1 (0.36) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL14945698 | 0.69 | DGAT1 (0.34) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL362095 | 0.68 | HDAC3 (0.34) | CYP2D6CA2DGAT1CA12CA14 | |
| SCHEMBL241533 | 0.67 | DGAT1 (0.46) | CYP2D6CA2CA1CA7DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | disclosed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | ZC3HAV1, TYR, ZC3HAV1L | CYP2D6 915/4885CA2 4348/4885CA1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.